News & Views
Agreement Expands Global Availability of Primary Cells
Feb 11 2019
A private label partnership for the manufacture and global commercialisation of an extensive range of hematopoietic primary cells has been agreed by Lonza and US company AllCells.
The addition of the entire AllCells research portfolio of products, which has expanded Lonza’s branded cell lines is available to scientists on a global scale to further their research across an array of applications, including drug discovery, toxicity testing, cell therapy and personalized medicine.
Hematopoietic primary cells play a vital role in advancing in vitro research as they closely reflect in vivo morphology, metabolism and growth characteristics. However, obtaining those cells requires researchers to find a variety of donors and perform a series of tedious cell isolations.
“With this partnership, we aim to enable straightforward access to a wealth of viable, ready-to-use hematopoietic cells, such as mobilised peripheral blood progenitor cells,” said Mary Riley, Director of Discovery Solutions at Lonza. “All researchers will need to do is thaw and culture, while also being able to take advantage of Lonza’s strong after-sales technical support.”
Don Klabunde, CEO at AllCells, added: “By leveraging our customisation expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality and with Lonza's extensive reach, we will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan